In immunohistochemistry (IHC), estrogen receptor (ER) is used to determine prognosis and as a predictive marker for anti-estrogen in breast cancer. The American Society of Clinical Oncology/College of American Pathologists (ASCO/CAP) recommends that the ER status of patients is determined on all invasive breast cancers and breast cancer recurrences [1]. It is recommended that the ER status of the tumor is considered positive if there are at least 1 % positive tumor nuclei in a tissue sample.
This APP provides the number of positive nuclei as well as the total number of nuclei. Additionally, intensity of the staining and an Allred Score can be exported.
The APP works fully automated in an integrated setting, from detecting the patient tissue and invasive tumor tissue to exporting the relevant outputs about the quantified nuclei.